Utilization Trends and Impact of Secukinumab Treatment on Clinical Outcomes in Biologic-Naive Patients with Psoriasis in a US Real-World Setting.

Bruce E StroberDhaval PatilRobert R McLeanMelissa Moore-ClingenpeelNing GuoEugenia LeviMark Lebwohl

Published in: Dermatology and therapy (2022)

The proportion of biologic-naive secukinumab initiators increased over time. Biologic-naive patients demonstrated similar improvements in clinical outcomes compared with biologic-experienced patients, suggesting that secukinumab may be considered as a first-line therapy for psoriasis.

Keyphrases

rheumatoid arthritis
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
ankylosing spondylitis
hiv infected
peritoneal dialysis
prognostic factors
patient reported outcomes
systemic lupus erythematosus
disease activity
antiretroviral therapy